Georgina Speake

Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non–Small-Cell Lung Cancer in Asia (IPASS)

Masahiro Fukuoka, Yi‐Long Wu, Sumitra Thongprasert et al. · Journal of Clinical Oncology · 2011 · 1.6K citations

Phase III Study of Gefitinib Compared With Intravenous Methotrexate for Recurrent Squamous Cell Carcinoma of the Head and Neck

J.S.W. Stewart, Ezra E.W. Cohen, Lisa Licitra et al. · Journal of Clinical Oncology · 2009 · 379 citations

Gefitinib Versus Vinorelbine in Chemotherapy-Naïve Elderly Patients With Advanced Non–Small-Cell Lung Cancer (INVITE): A Randomized, Phase II Study

Lucio Crinò, Federico Cappuzzo, Petr Zatloukal et al. · Journal of Clinical Oncology · 2008 · 217 citations

A comparison of ARMS and DNA sequencing for mutation analysis in clinical biopsy samples

Gillian Ellison, Emma Donald, Gael McWalter et al. · Journal of Experimental & Clinical Cancer Research · 2010 · 152 citations · Full text

AZD8931, an Equipotent, Reversible Inhibitor of Signaling by Epidermal Growth Factor Receptor, ERBB2 (HER2), and ERBB3: A Unique Agent for Simultaneous ERBB Receptor Blockade in Cancer

D. Mark Hickinson, Teresa Klinowska, Georgina Speake et al. · Clinical Cancer Research · 2010 · 118 citations